|Bid||18.04 x 2200|
|Ask||18.03 x 1300|
|Day's range||17.91 - 18.66|
|52-week range||12.52 - 36.55|
|Beta (5Y monthly)||0.88|
|PE ratio (TTM)||N/A|
|Earnings date||24 Oct 2022 - 28 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||52.19|
LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Citi’s 17th Annual BioPharma Conference, September 7 – 8, 2022 Members of uniQure’s management team, including Matt Kapusta, chief executive officer, and Ricardo Dolmetsch, Ph.D., president of research
The latest analyst coverage could presage a bad day for uniQure N.V. ( NASDAQ:QURE ), with the analysts making...
Shares of uniQure N.V. (NASDAQ: QURE) are crashing today, down by 32.6% as of 11:19 a.m. ET. The steep decline came after the gene therapy specialist provided its second-quarter update Monday morning. Investors weren't all that interested in uniQure's financial results.